Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

3H-1,2-dithiole-3-thione as a novel therapeutic agent for the treatment of experimental autoimmune encephalomyelitis.
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple SclerosisImpact of Fingolimod Therapy in Multiple Sclerosis.
Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
How Natalizumab Binds and Antagonizes α4 Integrins.
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
Cyclophosphamide for multiple sclerosis.
The natural course of clinically isolated syndrome in pediatric patients.
Mutations affecting segment number and polarity in Drosophila.
Tractography Analysis of 5 White Matter Bundles and Their Clinical and Cognitive Correlates in Early-Course Schizophrenia.
Multiple sclerosis causing a partial sixth nerve palsy.
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis-Report of Two Cases.
Association of IL4 and IL4R polymorphisms with multiple sclerosis susceptibility in Caucasian population: A meta-analysis.
New Drug Review 2010: Ustekinumab (Stelara, Centocor Ortho Biotech)
SMAD family proteins: the current knowledge on their expression and potential role in neoplastic diseases.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Twin studies and the heritability of MS: a conclusion.
The cytokines cardiotrophin-like cytokine/cytokine-like factor-1 (CLC/CLF) and ciliary neurotrophic factor (CNTF) differ in their receptor specificities.
Platelets provide a bounty of potential targets for therapy in multiple sclerosis.
Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis.
Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Cognitive impairment as unusual first manifestation in late-onset relapsing-remitting multiple sclerosis.
Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study.
The olfactory vector hypothesis of neurodegenerative disease: is it viable?
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Laquinimod Halted MS Disability But Not Relapses

Pages